Abcellera Biologics Inc ABCL

$12.55 +0.52 (4.37%)

Valuation

Market cap
3,846,435,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,691,400
Avg volume
7,182,938
Day's range
$11.93 – $12.79
Shares out
306,611,000
Stochastic %K
21%
Beta
1.41
Analysts
Strong Sell
Price target
$16.70

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

NumbingLosses Oct 12, 2:37 PM
$ABCL if folks are willing to invest and be patient up to FDA approval, this will prove to be an excellent investment. Just going to take a little time and patience.
0 replies
Ckkung71 Oct 12, 12:57 PM
$ABCL Today I will buy more if they push it down in opening
0 replies
CoffeeRocks Oct 12, 12:19 PM
$ABCL $BCTX $IOVA $SLS $VKTX Good day for Bios again
0 replies
SCSyndrome Oct 12, 8:23 AM
$ABCL k. Right on past $13 like it was no big deal. I love you Carl! You’re the freaking man!!!
0 replies
GuslovesBio Oct 12, 5:44 AM
$ABCL UBS initiated coverage of AbCellera (ABCL) with a Buy rating and $18 price target The firm believes ABCL635 is a “potentially transformative therapy” in menopausal hot flashes, with a $13B commercial opportunity in menopause by 2035. UBS models $3.3B menopause risk-adjusted 2035 sales versus the consensus at $1.5B. ABCL635 can capture greater share of a larger market than investors currently anticipate, the analyst tells investors in a research note.
1 replies
Odoji Oct 12, 4:07 AM
$ABCL soon 💉
0 replies
Jwa68 Oct 11, 2:23 AM
$GANX $COYA $ABCL "The upcoming patent cliff is creating urgency for acquirers to replenish pipelines, with the US drug market set to lose over $230 billion in revenue between 2025 and 2030 due to patent expirations. CVRs bridge this gap, allowing acquirers to offer competitive headline prices while deferring consideration to milestone-contingent payouts. For sellers, announced deal values are increasingly aspirational rather than guaranteed, making the probability-weighted expected value of contingent structures the critical metric in evaluating bids." The Rise of Contingent Value: CVRs and Earnouts Reshape Life Sciences M&A | Foley Hoag LLP https://share.google/m4YjuVHZxQ1EgWcBI
1 replies
erpy Oct 9, 4:06 PM
$ABCL Still going higher jmho.. Holding every share. Insiders recently loaded it wasnt for $12.5 jmho
1 replies